Your browser is no longer supported. Please, upgrade your browser.
Settings
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E67.40 EPS (ttm)5.51 Insider Own1.00% Shs Outstand109.15M Perf Week-8.69%
Market Cap40.53B Forward P/E22.77 EPS next Y16.31 Insider Trans-11.11% Shs Float77.66M Perf Month-8.38%
Income636.10M PEG3.26 EPS next Q2.61 Inst Own71.70% Short Float4.40% Perf Quarter-9.41%
Sales4.10B P/S9.88 EPS this Y85.10% Inst Trans-0.08% Short Ratio3.56 Perf Half Y-33.38%
Book/sh35.22 P/B10.54 EPS next Y41.45% ROA13.00% Target Price475.95 Perf Year-21.69%
Cash/sh9.58 P/C38.78 EPS next 5Y20.65% ROE19.20% 52W Range348.96 - 605.93 Perf YTD-31.60%
Dividend- P/FCF62.08 EPS past 5Y44.90% ROI16.00% 52W High-38.72% Beta1.02
Dividend %- Quick Ratio3.30 Sales past 5Y55.00% Gross Margin90.40% 52W Low6.41% ATR15.48
Employees4300 Current Ratio3.60 Sales Q/Q36.90% Oper. Margin30.00% RSI (14)38.34 Volatility4.45% 3.68%
OptionableYes Debt/Eq0.10 EPS Q/Q69.90% Profit Margin15.50% Rel Volume0.76 Prev Close384.52
ShortableYes LT Debt/Eq0.10 EarningsMay 05 BMO Payout0.00% Avg Volume958.18K Price371.32
Recom2.30 SMA20-8.19% SMA50-5.18% SMA200-23.69% Volume729,150 Change-3.43%
Apr-20-16Downgrade Wells Fargo Outperform → Market Perform
Mar-28-16Reiterated Canaccord Genuity Hold $525 → $450
Mar-17-16Reiterated Sun Trust Rbsn Humphrey Neutral $450 → $410
Mar-16-16Downgrade Chardan Capital Markets Neutral → Sell $375 → $325
Mar-15-16Initiated Gabelli & Co Buy $574
Mar-03-16Initiated Sun Trust Rbsn Humphrey Neutral $450
Feb-25-16Initiated Citigroup Buy $480
Feb-16-16Upgrade Chardan Capital Markets Sell → Neutral $400 → $375
Feb-10-16Reiterated RBC Capital Mkts Outperform $676 → $668
Feb-10-16Reiterated Leerink Partners Outperform $534 → $505
Feb-10-16Reiterated Barclays Equal Weight $610 → $425
Feb-09-16Reiterated Piper Jaffray Neutral $607 → $443
Jan-27-16Downgrade Canaccord Genuity Buy → Hold $700 → $525
Jan-25-16Downgrade Chardan Capital Markets Neutral → Sell $525 → $400
Jan-20-16Initiated Credit Suisse Neutral
Dec-04-15Initiated Wells Fargo Outperform
Nov-05-15Reiterated RBC Capital Mkts Outperform $665 → $676
Oct-02-15Downgrade Morgan Stanley Overweight → Equal-Weight $593
Sep-01-15Initiated Raymond James Outperform $615
Aug-31-15Downgrade Chardan Capital Markets Buy → Neutral $565
May-03-16 05:12PM  Regeneron Pharmaceuticals Inc Has a Lot to Prove on May 5 at Motley Fool
02:12PM  IBBs Large-Cap stocks: What Drove Regenerons Positive Results? Market Realist
10:16AM  Big pharma dominates ranking of stocks with best 5-year returns Reuters
09:08AM  Biotech Stocks Earnings Preview: REGN, LGND, ECYT & More Zacks
08:59AM  How to Trade 5 Biotech Stocks After a Fall -- Plus Jim Cramer's Take at TheStreet
08:06AM  Worst-Case Scenario for Regeneron: What If Eylea Sales Slow Down by 2018? Market Realist
May-02-16 11:54AM  Regeneron (REGN) Q1 Earnings: Stock Likely to Disappoint Zacks
10:03AM  Regeneron Arthritis Pain Drug Scores In Mid-Stage Trial at Investor's Business Daily
08:11AM  Regeneron pain drug clears late-stage trial Reuters
07:00AM  Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain PR Newswire
Apr-29-16 06:06PM  Understanding Regenerons Operating Expenses and Margins Market Realist
02:22PM  ETFs with exposure to Regeneron Pharmaceuticals, Inc. : April 29, 2016 at Capital Cube
09:30AM  Regeneron Announces Upcoming 2016 Investor Conference Presentations PR Newswire
Apr-28-16 11:07AM  Can Regeneron Continue Its Sales Growth Momentum in 2016? Market Realist
09:08AM  Whats Regeneron Expecting for Revenue in 1Q16? Market Realist
08:13AM  Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : REGN-US : April 28, 2016 at Capital Cube
Apr-27-16 03:35PM  How to Trade Regeneron's Pullback at TheStreet
12:32PM  Whos Bullish on Regeneron ahead of Its 1Q16 Results? Market Realist
12:32PM  Understanding Regenerons Share Price Movement after Its 4Q16 Results Market Realist
Apr-26-16 05:39PM  Regeneron Billionaires Got Raises in 2015 Before Shares Fell at Bloomberg
Apr-22-16 01:23PM  3 Stocks to Buy in a Crashing Market at Motley Fool
Apr-16-16 09:00AM  'Mad Money' Lightning Round: Con Ed, Regeneron Are My Picks at TheStreet
Apr-15-16 09:00PM  High Times for a Lot of Companies; Why Facebook's Stock Is Falling: Jim Cramer's Best Blogs at TheStreet
11:07AM  A Look at Ionis Pharmaceuticals Nusinersen
09:30AM  Regeneron to Report First Quarter 2016 Financial and Operating Results and Host Conference Call and Webcast on May 5, 2016 PR Newswire
09:00AM  How Gilead Can Double In 3 Years at Forbes
Apr-14-16 05:45PM  This is the most expensive drug in America at MarketWatch
10:03AM  Better Buy: MannKind Corporation vs. Sanofi at Motley Fool
08:10AM  These 5 Big Stocks Are Breaking Out at TheStreet
Apr-13-16 01:26PM  Regeneron and Intellia Therapeutics Will Develop CRISPR/Cas
Apr-12-16 07:02PM  Cramer: Here's Why Facebook's Stock Has Been Falling
04:55PM  Regeneron, Intellia Strike Deal for CRISPR/Cas Platform
03:03PM  Regeneron's Bold Bet on the Future of Medicine at Motley Fool
01:24PM  How Regenerons Eylea Growth, Amgen, Sanofi Deal Figure In Stock
09:02AM  3 Biotech Stocks to Buy in April at Motley Fool
07:05AM  Cambridge gene-editing firm eyes IPO, discloses Novartis deal at bizjournals.com
Apr-11-16 06:30PM  [$$] Gene-Editing Company Intellia Discloses IPO Plan, Regeneron Pact at The Wall Street Journal
04:05PM  Regeneron and Intellia Therapeutics Announce Collaboration to Discover and Develop CRISPR/Cas Therapeutics PR Newswire
11:44AM  Shares of Regeneron Pharmaceuticals, Inc. Struggled in March -- Here's Why at Motley Fool
Apr-09-16 12:06AM  How Has Incytes Jakafi Performed in the US?
Apr-07-16 11:51AM  Is Biotech Back? at Barrons.com
09:30AM  The Zacks Analyst Blog Highlights: Gilead, Regeneron, Medivation and Intercept
Apr-06-16 07:01PM  Cramer: See What Happens When Takeover Talk Gets Going? +5.83%
02:26PM  Biotech: The Waiting Game? at Barrons.com
02:08PM  Biotech Stock Roundup: Gilead's HIV Drug Approved, Regeneron Up on Positive Data
09:08AM  Regenerons Stock Reacts to Dupilumab Phase 3 Trials
Apr-05-16 07:04PM  Cramer: Hope for biotech in the blast zone at CNBC
07:01PM  Jim Cramer's 'Off the Charts': Biotech Gets a Short-Term Bottom at TheStreet
04:21PM  This Amgen News Could Be a Game-Changer in its Fight Against Sanofi and Regeneron Pharmaceuticals at Motley Fool
03:42PM  Regeneron Pharmaceuticals, Inc. Value Analysis (NASDAQ:REGN) : April 5, 2016
01:44PM  2 Biotech Companies That Could Profit if Their Skin Treatments Are Successful at TheStreet
12:21PM  Alexion Pharmaceuticals New Data from Phase 2 Trial of Strensiq
07:22AM  Forget Regeneron Pharmaceuticals, Inc.: These 2 Stocks Are Better Buys at Motley Fool
Apr-04-16 05:28PM  Pfizer's PCSK9 Inhibitor Positive in Second Phase III Study
03:40PM  Regeneron, Sanofi Up, Eczema Drug Tops Phase III Studies
03:25PM  A Biotech Breakout? at Barrons.com
12:22PM  Biotech: Time to Buy? at Barrons.com
10:01AM  Better Buy: Regeneron Pharmaceuticals, Inc. vs. Amgen at Motley Fool
09:40AM  [$$] Clinical Development News, March 28-April 1 at The Wall Street Journal
08:02AM  Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : REGN-US : April 4, 2016
12:47AM  [$$] Regenerons Blockbuster Dreams Get Brighter at The Wall Street Journal
Apr-03-16 12:41PM  [$$] Regeneron's Blockbuster Dreams Get Brighter at The Wall Street Journal
Apr-02-16 02:03PM  The Secrets Out: These Biotech Marvels Have Fallen Too Far
Apr-01-16 06:30PM  Why Regeneron Pharmaceuticals, Tronox, and Office Depot Jumped Today at Motley Fool +12.43%
06:29PM  Stocks Up; Apple Turns 40, Tesla Pre-Orders Impress
04:30PM  US STOCKS-Wall Street off to a solid start in April Reuters
04:08PM  Regeneron Pharmaceuticals Inc Jumps on Positive Clinical Data at Motley Fool
03:38PM  Regeneron Pharmaceuticals (REGN) Stock Skyrockets on Positive Eczema Drug Results at TheStreet
03:19PM  Stocks reverse higher on strong jobs, manufacturing data
03:07PM  US STOCKS-Wall Street extends seven-week rally after jobs data
03:07PM  No April Fooling: Tesla, Nasdaq Steer Stock Market To Gains
02:42PM  Regeneron Delivers A 'Blockbuster' Win In Eczema at Motley Fool
01:01PM  Regeneron Soars After Drug Clears Eczema, Sparks Market Size Debate
11:34AM  [$$] Regeneron, Sanofi Say Eczema Drug Met Targets in Late-Stage Studies at The Wall Street Journal
11:30AM  US STOCKS-Wall St up slightly as investors assess economic data
11:19AM  Healthcare Investor Sam Isaly Was Wrong About These 2 Stocks; Makes a Lot of Money on Freshly-Acquired Insurer at Insider Monkey
10:35AM  Regeneron Soars on Successful Drug Trials at Barrons.com
10:00AM  Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
07:55AM  Early movers: BBRY, HOT, TSLA, URBN, FB, PGR & more at CNBC
06:00AM  Regeneron's Eczema Data Look Great. Don't Believe Me? Ask A Patient at Forbes
01:08AM  Regeneron's Skin-Clearing Drug Hits Goals in Final-Stage Trials at Bloomberg
01:00AM  Regeneron, Sanofi eczema drug clears hurdles in big trials Reuters
01:00AM  Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Two Phase 3 Trials in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients PR Newswire
Mar-31-16 02:38PM  Pisani: Can biotech recover from big slide? at CNBC
01:55PM  [$$] Telecoms and utilities lead quarterly gains for S&P 500 at Financial Times
01:27PM  Worst Stocks Of The First Quarter
Mar-29-16 02:50PM  Regeneron: Injunction Time Again at Barrons.com
09:17AM  How investors should pick stocks to beat a go-nowhere market
06:07AM  REGENERON PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
Mar-28-16 01:00PM  Regeneron's Chart Has Degenerative Look
09:30AM  The Zacks Analyst Blog Highlights: Gilead, Amgen, Regeneron, Ionis and Biogen
Mar-25-16 10:30AM  Gilead, Biogen Troubles Remind Investors Why Strong Drug Patents Are Vital at TheStreet
Mar-24-16 06:23PM  XBI Large-Cap News: Amid Beatdowns, Regeneron Has an Announcement
03:15PM  Gilead & Biogen's Patent Woes, Amgen Scores Win in Patent Litigation
10:00AM  Regeneron/Sanofi Report Positive Phase III Data on Praluent
08:00AM  Regeneron and Bayer To Jointly Develop Novel Combination Therapy for Eye Diseases PR Newswire
Mar-23-16 07:00AM  8 Wide-Moat Stocks of Tomorrow at Morningstar
02:17AM  Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Praluent® (alirocumab) Study in Patients Undergoing LDL Apheresis Therapy at noodls
02:07AM  Sanofi and Regeneron Announce Positive Topline Results from Phase 3 Praluent® (alirocumab) Study in Patients Undergoing LDL Apheresis Therapy at noodls
02:00AM  Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Praluent® (alirocumab) Study in Patients Undergoing LDL Apheresis Therapy PR Newswire
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Its marketed products include EYLEA injection for the treatment of neovascular age-related macular degeneration and diabetic macular edema, as well as macular edema following retinal vein occlusion; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of low-density lipoprotein cholesterol; and ARCALYST for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and childrens. The company is also developing trap-based clinical product EYLEA for the treatment of Neovascular Glaucoma; antibody-based clinical products comprising Praluent, Sarilumab, Dupilumab, REGN2810, REGN2176-3, Fasinumab, REGN2222, Evinacumab, REGN1033, REGN1908-1909, REGN1979, and Nesvacumab/aflibercept; and ZALTRAP, an injection for intravenous infusion for the treatment of patients with metastatic colorectal cancer. It has collaborations with Sanofi, Bayer HealthCare, and Mitsubishi Tanabe Pharma Corporation for the development of antibody-based clinical based products. The company was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GOLDSTEIN JOSEPH LDirectorApr 06Option Exercise177.821,000177,82014,000Apr 07 04:19 PM
GOLDSTEIN JOSEPH LDirectorApr 06Sale425.002,000850,00013,000Apr 07 04:19 PM
GOLDSTEIN JOSEPH LDirectorApr 01Option Exercise177.822,000355,64016,000Apr 04 04:16 PM
GOLDSTEIN JOSEPH LDirectorApr 01Sale400.002,000800,00014,000Apr 04 04:16 PM
GOLDSTEIN JOSEPH LDirectorMar 21Option Exercise177.822,000355,64016,000Mar 21 04:27 PM
GOLDSTEIN JOSEPH LDirectorMar 21Sale375.002,000750,00014,000Mar 21 04:27 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 29Option Exercise52.033,954205,72710,820Dec 29 07:44 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 29Sale552.083,9542,182,9246,866Dec 29 07:44 PM
Aberman Michael SSVP Strategy Investor RelationDec 17Option Exercise24.004,00096,00016,498Dec 18 04:28 PM
Powchik PeterSVP Clinical Development & RegDec 16Option Exercise52.031,92199,95017,742Dec 18 04:27 PM
McCorkle Douglas SVP Controller and Asst TreasurDec 16Option Exercise52.031,92199,9506,866Dec 18 04:28 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 16Option Exercise52.031,92199,950501,921Dec 18 04:26 PM
Van Plew Daniel PSVP & General Mgr Industrial ODec 16Option Exercise52.031,92199,9501,921Dec 18 04:27 PM
STAHL NEILEVP Research and DevelopmentDec 16Option Exercise52.031,92199,95027,594Dec 18 04:27 PM
BROWN MICHAEL SDirectorDec 10Option Exercise177.823,000533,4603,000Dec 11 04:14 PM
BROWN MICHAEL SDirectorDec 10Sale546.453,0001,639,3650Dec 11 04:14 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriDec 02Sale549.0343,34823,799,539500,000Dec 04 04:13 PM
SING GEORGE LDirectorNov 18Option Exercise19.693,00059,070115,772Nov 20 04:04 PM
SING GEORGE LDirectorNov 18Sale580.00500290,0004,500Nov 20 04:04 PM
SING GEORGE LDirectorNov 18Sale580.003,0001,740,000112,772Nov 20 04:04 PM
VAGELOS P ROYChairman of the BoardNov 18Sale587.9017,24010,135,312334,611Nov 19 04:20 PM
STAHL NEILEVP Research and DevelopmentNov 09Sale560.0522,10112,377,55922,029Nov 09 05:10 PM
STAHL NEILEVP Research and DevelopmentNov 06Sale563.0020,00011,260,06844,130Nov 09 05:10 PM
STAHL NEILEVP Research and DevelopmentNov 05Option Exercise28.29100,0002,828,50097,029Nov 09 05:10 PM
VAGELOS P ROYChairman of the BoardNov 03Sale580.233,9852,312,217351,851Nov 04 04:05 PM
VAGELOS P ROYChairman of the BoardNov 02Sale580.1813,2577,691,446355,836Nov 04 04:05 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriNov 02Sale571.6143,34824,778,125543,348Nov 03 04:20 PM
YANCOPOULOS GEORGEPresident Regeneron LaboratoriOct 30Option Exercise11.64182,8182,128,002682,818Nov 03 04:20 PM
BROWN MICHAEL SDirectorSep 21Option Exercise57.113,000171,3303,000Sep 22 02:39 PM
BROWN MICHAEL SDirectorSep 21Sale551.553,0001,654,6500Sep 22 02:39 PM
BAKER CHARLES ADirectorSep 17Option Exercise18.615,00093,05014,000Sep 18 04:06 PM
BAKER CHARLES ADirectorSep 17Sale550.005,0002,750,0009,000Sep 18 04:06 PM
SCHLEIFER LEONARD SPresident & CEOSep 02Option Exercise402.697,2262,909,83849,313Sep 03 04:59 PM
LAROSA JOSEPH JSVP General Counsel and SecretSep 01Option Exercise59.201,68999,98916,756Sep 02 04:04 PM
Powchik PeterSVP Clinical Development & RegAug 14Sale573.3823,48513,465,86615,821Aug 17 04:01 PM
Powchik PeterSVP Clinical Development & RegAug 13Option Exercise117.3360,3617,082,07046,299Aug 17 04:01 PM
POON CHRISTINE ADirectorAug 12Sale564.1611263,186790Aug 12 04:45 PM
POON CHRISTINE ADirectorAug 11Option Exercise273.67470128,6251,125Aug 12 04:45 PM
GILMAN ALFRED GDirectorAug 06Option Exercise57.115,000285,55013,912Aug 07 06:15 PM
GILMAN ALFRED GDirectorAug 06Sale587.125,0002,935,6018,912Aug 07 06:15 PM
Terifay Robert JSVP CommercialAug 06Sale588.9713,4237,905,78123,293Aug 07 06:14 PM
Terifay Robert JSVP CommercialAug 05Option Exercise30.6332,500995,47552,529Aug 07 06:14 PM
Tessier-Lavigne MarcDirectorAug 05Option Exercise57.115,000285,5506,187Aug 05 08:55 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 05Option Exercise270.435,0001,352,1509,745Aug 05 08:58 PM
Landry Robert ESVP Finance & CFOAug 05Option Exercise272.704,0001,090,80011,099Aug 06 09:00 PM
Landry Robert ESVP Finance & CFOAug 05Sale592.844,0002,371,3507,099Aug 06 09:00 PM
McCorkle Douglas SVP Controller and Asst TreasurAug 05Sale585.535,0002,927,6484,945Aug 05 08:58 PM
Tessier-Lavigne MarcDirectorAug 05Sale590.265,0002,951,2751,187Aug 05 08:55 PM
GOLDSTEIN JOSEPH LDirectorAug 04Sale586.002,0001,172,00014,000Aug 05 10:03 AM
GOLDSTEIN JOSEPH LDirectorJul 15Sale550.002,0001,100,00016,000Jul 15 04:09 PM
GOLDSTEIN JOSEPH LDirectorJun 22Sale526.852,0001,053,70018,000Jun 22 05:02 PM
SING GEORGE LDirectorMay 27Option Exercise19.695,00098,450117,772May 29 04:19 PM
SING GEORGE LDirectorMay 27Sale515.005,0002,575,000112,772May 29 04:19 PM
INGRAM ROBERT ALEXANDERDirectorMay 27Sale513.391,379707,9651,500May 27 04:02 PM
INGRAM ROBERT ALEXANDERDirectorMay 22Option Exercise293.536,6671,956,9656,667May 27 04:02 PM
McCorkle Douglas SVP Controller and Asst TreasurMay 22Option Exercise174.0113,4642,342,90217,481May 26 04:31 PM
McCorkle Douglas SVP Controller and Asst TreasurMay 22Sale515.6013,0006,702,8004,481May 26 04:31 PM
GOLDSTEIN JOSEPH LDirectorMay 22Sale514.284,0002,057,10020,000May 26 04:30 PM
BROWN MICHAEL SDirectorMay 15Option Exercise57.115,000285,5505,000May 18 04:50 PM
BROWN MICHAEL SDirectorMay 15Sale495.005,0002,475,0000May 18 04:50 PM